Medtronic plc
MDT- Exchange
- NYSE
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001613103
In the last 90 days, Medtronic plc insiders filed 0 open-market purchases and 2 sales; 2,149 institutions reported holding it in 13F filings for Q2 2026, worth $86.8B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $396.8K in total
- 2
- 13F holdersQ2 2026, −78 vs. previous quarter
- 2,149
- 13F valueReported value at the end of Q2 2026
- $86.8B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MDT, Q2 2026
No superinvestor reported holding MDT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Medtronic plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:17 PM ET | Sep 16 | 1 day | Kiil Harry SkipEVP & President Cardiovascular | SSale | −1.48K | $93.65 | −$138.9K | −3.4%42.2K after | |
| Jul 9, 2026 (view filing)4:26 PM ET | Jul 8 | 1 day | Walter Matthew R.SVP, Chief HR Officer | SSale | −3.10K | $83.15 | −$257.9K | −8.0%35.7K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Kiil Harry SkipEVP & President Cardiovascular | SSale | −4.19K | $80.44 | −$337.0K | −10.1%37.2K after | 2 lots |
| Feb 26, 2026 (view filing) | Feb 19 | 7 daysLate | Kiil Harry SkipEVP & President Cardiovascular | SSale | −52.5K | $97.71 | −$5.13M | −61.6%32.8K after | 5 lots |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Smith Gregory LEVP Global Ops & Supply Chain | SSale | −30.0K | $101.95 | −$3.06M | −39.5%46.0K after | 7 lots |
| Sep 5, 2025 (view filing) | Sep 3 | 2 days | Kiil Harry SkipEVP & President Cardiovascular | SSale | −8.61K | $91.58 | −$788.0K | −19.5%35.6K after | 2 lots |
| Aug 25, 2025 (view filing) | Aug 22-25 | 3 days | Jellison William RDirector | PPurchase | +5.00K | $92.55 | +$462.8K | New position5.00K after | 2 lots |
| Jan 27, 2025 (view filing) | Jan 24 | 3 days | Wall Brett A.EVP & Pres Neuroscience | SSale | −12.4K | $90.00 | −$1.12M | −23.3%41.0K after | 10b5-1 |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Wall Brett A.EVP & Pres Neuroscience | SSale | −9.85K | $80.41 | −$792.0K | −19.5%40.7K after | 2 lots10b5-1 |
| Jun 11, 2024 (view filing) | Jun 7 | 4 days | Martha GeoffreyChairman and CEO | SSale | −19.1K | $83.77 | −$1.60M | −11.8%143.3K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Medtronic plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 114,020,787 | $8.92B | 0.13% | +838,220+0.7% | Added |
| Vanguard Capital Management LLC | 83,816,735 | $6.56B | 0.14% | +482,902+0.6% | Added |
| State Street Corp | 63,399,315 | $5.01B | 0.15% | +1,658,301+2.7% | Added |
| Vanguard Portfolio Management LLC | 34,059,967 | $2.66B | 0.12% | +609,409+1.8% | Added |
| Massachusetts Financial Services Co | 19,872,600 | $2.61B | 0.83% | −1,564,999−7.3% | Reduced |
| Geode Capital Management, LLC | 30,192,015 | $2.35B | 0.13% | +1,455,674+5.1% | Added |
| JPMorgan Chase & Co | 27,784,471 | $2.25B | 0.13% | −23,189,070−45.5% | Reduced |
| Bank of America Corp | 21,322,401 | $1.67B | 0.11% | −4,692,602−18.0% | Reduced |
| Morgan Stanley | 19,444,871 | $1.52B | 0.08% | −1,272,158−6.1% | Reduced |
| Deutsche Bank AG | 18,449,877 | $1.44B | 0.42% | −552,537−2.9% | Reduced |